Research programme: janus kinase inhibitors - Aclaris Therapeutics/ JAKPharmAlternative Names: JAK3 inhibitors - Aclaris Therapeutics/JAKPharm
Latest Information Update: 01 Jun 2016
At a glance
- Originator JAKPharm
- Developer Aclaris Therapeutics
- Mechanism of Action Janus kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Alopecia